anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to fructus-hippophae oil composite soft capsules. In 300 mg of every fructus-hippophae oil composite soft capsule, the components measured by the weight of mg are 50 mg of grape seed extract, 76.7 mg of vitamin E, 100 mg of fructus-hippophae oil, 0.225 mg of titanium dioxide and 0.075 mg of edible pigment; the content of suspension is 60 mg of soybean oil and 13 mg of edible wax; the content of soft gum casing is 115 mg of gelatin, 37 mg of glycerin and 78 mg of purifying water. At present, procyanidin is discovered that the procyanidin has direct or indirect preventing and therapeutic functions for near 70 diseases. The content of procyanidin extracted by grape seeds is up to 95%. The fructus-hippophae oil composite soft capsules can clear free radical, resist oxidation, delay aging, remove spot and wrinkle and reduce pigmentation and chloasma. The fructus-hippophae oil composite soft capsules can effectively lighten various senile symptoms, has special effect on delaying aging, and simultaneously, has a function for protecting gastric mucosa.
PCT No. PCT/DE81/00089 Sec. 371 Date Feb. 19, 1982 Sec. 102(e) Date Feb. 19, 1982 PCT Filed Jun. 11, 1981 PCT Pub. No. WO82/00035 PCT Pub. Date Jan. 7, 1982.A natural, edible dye, characterized by particular infrared and ultraviolet spectra and a method for its production, in which cell walls of the skins of colored beans of the genus Phaseolus, such as black beans, are destroyed, the released dye is extracted with water or an aqueous solution of a weak organic acid after weak acidulation, the obtained extract is separated from the skin residues, and the solution is concentrated and dried. The dye is used, in particular, for coloring foodstuffs and snack foods, beverages, pharmaceutical and cosmetic products, and for coloring textiles, paper and leather.
Up to 80% of patients under immune checkpoint inhibitors (ICI) face resistance. In this context, stereotactic ablative radiotherapy (SABR) can induce an immune or abscopal response. However, its molecular determinants remain unknown. We present early results of a translational study assessing biomarkers of response to combined ICI and SABR (I-SABR) in liquid biopsy from oligoprogressive patients in a prospective observational multicenter study. Cohort A includes metastatic patients in oligoprogression to ICI maintaining the same ICI due to clinical benefit and who receive concomitant SABR. B is a comparative group of oligometastatic patients receiving only SABR. Blood samples are extracted at baseline (T1), after the first (T2) and last (T3) fraction, two months post-SABR (T4) and at further progression (TP). Response is evaluated by iRECIST and defined by the objective response rate (ORR)-complete and partial responses. We assess peripheral blood mononuclear cells (PBMCs), circulating cell-free DNA (cfDNA) and small RNA from extracellular vesicles. Twenty-seven patients could be analyzed (cohort A: n = 19; B: n = 8). Most were males with non-small cell lung cancer and one progressing lesion. With a median follow-up of 6 months, the last ORR was 63% (26% complete and 37% partial response). A decrease in cfDNA from T2 to T3 correlated with a good response. At T2, CD8+PD1+ and CD8+PDL1+ cells were increased in non-responders and responders, respectively. At T2, 27 microRNAs were differentially expressed. These are potential biomarkers of response to I-SABR in oligoprogressive disease.
Each test period will consist of 2 in-clinic visits to assess the pharmacokinetics of one of the assigned study products. On Day 1 of each test period participants will provide a pre-dose blood sample within 90-minutes before a dose of study product, followed by PK blood sample collections for the next 10 h. Participants will return to the clinic the following day for the 24 h PK blood sample collection. Each test period will be separated by a washout period.
Sixty subjects will be sequentially enrolled into one of five study groups (i.e., Group 1, Group 2, Group 3, Group 4, or Group 5) with 10 subjects per group in Groups 1-4 and 20 subjects in Group 5. Within each study group, subjects will be randomized to a treatment assignment of either AERAS-404 or placebo control at a ratio of 4:1 (Groups 1-4) or two different dose amounts of AERAS-404 or placebo control at a ratio of 9:9:2 (Group 5) administered by intramuscular injection on Study Day 0 and Study Day 56. The principal investigator will determine an appropriate interval between the vaccinations such that the entire group is not dosed at the same time. All subjects will receive the same treatment on Study Day 0 as they receive on Study Day 56. All subjects will be followed for safety and immunogenicity evaluations for 182 days. A total of eleven clinic visits are planned (excluding screening) for all subjects
Disclosed is a Madin-Darby canine kidney (MDCK)-derived cell line. The MDCK-derived cell line is derived from MDCK cells deposited under accession number ATCC CCL-34. The MDCK-derived cell line can be prepared by serum-free culture and suspension culture. Preferably, the MDCK-derived cell line has low or no tumorigenicity. The MDCK-derived cell line is preferably selected from MDCK Sky1023, MDCK Sky10234 and MDCK Sky3851. Further disclosed are a culture method for growing the MDCK-derived cells and a method for producing a vaccine virus using the MDCK-derived cells.
PURPOSE:To industrially and efficiently obtain a flaky barium sulfate provided with a particle property suitable for applications such as to pigments and cosmetics. CONSTITUTION:The crystal particle of the barium sulfate has >=5 aspect ratio, >=2mum average particle diameter in planar shape and is free from any exceptional projecting or recessed part on the peripheral part of the planar face, and the flaky barium sulfate is provided with the property revealing streamline by streamline evaluating method when the crystal particle is made into a water based slurry. The flaky barium sulfate is produced by adding a barium salt solution to a sulfate solution simultaneously in such a concn. and vol. ratio that the concn. of a formed slurry of barium sulfate is made <=5wt.%, and the quantity of sulfate ion excessive to Ba ion in the system is set to 0.1-3g/l based on sulfate ion through the reaction process in this barium sulfate forming reaction by the barium salt solution and the sulfate solution.
There will only be one group in the feasibility study (i.e. all 50 patients recruited will receive the intervention).
Rescue treatments for status asthmaticus remain limited. Current literature has mainly focused on using extracorporeal membrane oxygenation (ECMO) as a primary modality of care for these patients. Low-flow extracorporeal CO 2 removal (ECCO 2 R) systems are an attractive option to improve refractory hypercapnic respiratory acidosis because of status asthmaticus. This is a retrospective case series that describes the feasibility and efficacy of the use of a low-flow ECCO 2 R device, the Hemolung Respiratory Assist System, in patients with refractory hypercapnic respiratory failure because of status asthmaticus. Eight patients were treated with the Hemolung Respiratory Assist System in eight separate locations globally. Seven (88%) of the patients survived to discharge in this case series. Both CO 2 and pH resolution were seen in 6 hours. None of the ECCO 2 R runs were stopped because of mechanical- or device-related complications. One patient necessitated transition to ECMO. Low-flow ECCO 2 R systems is an effective option for resolution of refractory hypercapnia in status asthmaticus. Use of these systems are also associated with a survival rate of close to 90% in patients with status asthmaticus.
BACKGROUND: The immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is crucial for preventing infections and relapse and enhancing graft-versus-tumor effects. B cells play an important role in humoral immunity and immune regulation, but their reconstitution after allo-HSCT has not been well studied.
METHODS: In this study, we analyzed the dynamics of B cells in 252 patients who underwent allo-HSCT for 2 years and assessed the impact of factors on B-cell reconstitution and their correlations with survival outcomes, as well as the development stages of B cells in the bone marrow and the subsets in the peripheral blood.
RESULTS: We found that the B-cell reconstitution in the bone marrow was consistent with the peripheral blood (p = 0.232). B-cell reconstitution was delayed by the male gender, age >50, older donor age, the occurrence of chronic and acute graft-versus-host disease, and the infections of fungi and cytomegalovirus. The survival analysis revealed that patients with lower B cells had higher risks of death and relapse. More importantly, we used propensity score matching to obtain the conclusion that post-1-year B-cell reconstitution is better in females. Meanwhile, using mediation analysis, we proposed the age-B cells-survival axis and found that B-cell reconstitution at month 12 posttransplant mediated the effect of age on patient survival (p = 0.013). We also found that younger patients showed more immature B cells in the bone marrow after transplantation (p = 0.037).
CONCLUSION: Our findings provide valuable insights for optimizing the management of B-cell reconstitution and improving the efficacy and safety of allo-HSCT.
<P>PROBLEM TO BE SOLVED: To provide an artificial lymph node which continues the effect of treating cancer in the living body.  <P>SOLUTION: The method for manufacturing an artificial lymph node inducing a cancer antigen-specific immune reaction comprises (a) a step of immunizing a nonhuman animal with the use of a cancer antigen and an adjuvant inducing cellular immunity and (b) a step of transplanting an artificial lymph node material composed of a polymer biomaterial containing a cytokine-producing stromal cell and a dendritic cell into the immunized nonhuman animal. The artificial lymph node inducing a cancer antigen-specific immune reaction is obtained by the above manufacturing method. A cancer treating agent comprises the above artificial lymph node. A kit for manufacturing an artificial lymph node for treating cancer comprises (a) a cancer antigen, (b) an adjuvant inducing cellular immunity, (c) a cytokine-expressing vector and a stromal cell, or a cytokine-producing stromal cell, (d) a dendritic cell, and (e) a polymer biomaterial.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The invention discloses an implanted dual sustained-release granule preparation of 10-hydroxycamptothecine, an antitumor drug, and a preparation method thereof. The invention relates to pharmaceutical preparation and provides the dual sustained-release granule preparation of 10-hydroxycamptothecine that has long releasing time, stable releasing and high utilization ratio of the drug and the preparation method thereof. The preparation is administrated in the manner of implanting after the operation of tumor nidus, thus realizing local target administration to reduce toxic and side effects on the whole body and prevent the recurrence of the tumor. The ingredients of preparation are drug-loaded microspheres, chitosan, lecithin and collagen. The drug-loaded microspheres contain hydroxycamptothecine and polylactic acid that are dissolved in organic solvent in proportion. Initial latex is prepared by dialysis; deposit is collected by centrifugation; and the drug-loaded microsphere is obtained by freeze drying. Afterwards, the chitosan, the collagen and the lecithin with water solubility are added into acetic acid resolution in proportion; and the drug-loaded microsphere is mixed with the solution. After stamping and drying, solid strip preparation is obtained. And the preparation is cut up and stored according to the specifications of the preparation.
Increases in weight have been observed in clinical trials. Patients receiving quetiapine should receive regular monitoring of weight [see Patient Counseling Information (17)].

In some patients, a worsening of more than one of the metabolic parameters of weight, blood glucose and lipids was observed in clinical studies. Changes in these parameters should be managed as clinically appropriate.

Adults: In clinical trials with quetiapine the following increases in weight have been reported. 

Children and Adolescents: In two clinical trials with quetiapine, one in bipolar mania and one in schizophrenia, reported increases in weight are included in the table below. 

The mean change in body weight in the schizophrenia trial was 2.0 kg in the quetiapine group and -0.4 kg in the placebo group and in the bipolar mania trial it was 1.7 kg in the quetiapine group and 0.4 kg in the placebo group. 

In an open-label study that enrolled patients from the above two pediatric trials, 63% of patients (241/380) completed 26 weeks of therapy with quetiapine. After 26 weeks of treatment, the mean increase in body weight was 4.4 kg. Forty-five percent of the patients gained ≥ 7% of their body weight, not adjusted for normal growth. In order to adjust for normal growth over 26 weeks an increase of at least 0.5 standard deviation from baseline in BMI was used as a measure of a clinically significant change; 18.3% of patients on quetiapine met this criterion after 26 weeks of treatment.

When treating pediatric patients with quetiapine for any indication, weight gain should be assessed against that expected for normal growth.
This will be a multicenter, double-blind (neither investigator nor patient knows which treatment the patient receives), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), randomized (patients are assigned different treatments based on chance), multiple-dose, proof-of-mechanism (POM) study in pAD. Approximately 24 outpatients (n=8/treatment group) diagnosed with pAD, according to the inclusion and exclusion criteria, will participate in this 4-week treatment study. For all enrolled patients, this study will consist of an 8-week eligibility screening period, a 4-week double-blind treatment period, and a follow-up examination (7-14 days after the last dose). Patients will be assigned randomly to 1 of 3 treatment groups: placebo, JNJ-54861911 10 mg once daily, or JNJ-54861911 50 mg once daily. Safety assessments will be performed throughout the study. The maximal study duration for a patient will be 14 weeks.
This is a Phase 1, randomized, double-blind, placebo-controlled trial comparing a single intra-articular 2.0 mL injection of either AlloGen or sterile saline. Patients will be evaluated at baseline, 1 week, 6 weeks, 12 weeks, and 26 weeks. The patient will remain blinded to his or her treatment throughout the study duration. The investigator/assessor will also remain blinded throughout the treatment period. Only the individual(s) preparing the injection will not be blinded. Black tape over the injection syringe will mask the study treatment.

Up to 30 adult patients with osteoarthritis of one knee that has failed to adequately respond to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen, will be enrolled at up to 5 sites in the US. The first 6 subjects will be staggered to evaluate any significant toxicity. Any adverse event data collected will be reviewed by the Data Safety Monitoring Board (DSMB) prior to treating the subsequent subject. Cumulative safety data from these 6 subjects will be reviewed by the DSMB.
A piece of food stuck in the esophagus (the tube connecting the mouth to the stomach) is a relatively common occurrence, estimated at a rate of 13 episodes per 100,000 people per year, mostly men, and usually attributed to swallowed meat. The current standard of care for patients presenting to an Emergency Department with this problem includes a trial of medication, usually glucagon but sometimes a carbonated beverage, an injection of nitroglycerin, or benzodiazepines. The medical interventions mentioned above have not been shown to be significantly effective and have unwanted side effects; glucagon is known to cause nausea and vomiting and benzodiazepines can cause sedation and depressed breathing. If the medication fails to relieve the problem, the patient may require a procedure called endoscopy, where a video scope and retrieval tool are inserted into the esophagus to remove the piece of food. There is significant risk associated with endoscopy, including the risks of anesthesia as well as with the physical procedure itself. Endoscopy also results in a prolonged hospital stay due to the time required for the procedure, as well as from anesthesia recovery. The ideal treatment would be a safe, inexpensive, quickly effective medication without significant side effects that could be administered without sedation or extensive monitoring. Oral nitroglycerin solution might just be that intervention.
Glucocorticoid-induced osteonecrosis of the femoral head (SONFH) is the most prevalent form of secondary osteonecrosis affecting the femoral head. Glucocorticoids can cause damage to both vascular endothelial cells and osteoblasts. Previous studies have demonstrated that silicon can improve the resistance of vascular endothelial cells to oxidative stress and positively impact bone health. However, the impact of silicon on SONFH has yet to be investigated. We examined the influence of ortho-silicic acid (OSA, Si(OH)4) on the apoptosis and proliferation of vascular endothelial cells after glucocorticoid induction. Additionally, we evaluated the expression of apoptosis-related genes such as cleaved-caspase-3, Bcl-2 and Bax. The impact of glucocorticoids and OSA on the function of vascular endothelial cells was evaluated through wound healing, transwell and angiogenesis assays. Osteogenic function was subsequently evaluated through alizarin red staining, alkaline phosphatase staining and expression levels of osteogenic genes like RUNX2 and ALP. Moreover, we investigated the potential role of OSA in vivo using the SONFH animal model. At concentrations below 100 μM, OSA exhibits no toxicity on vascular endothelial cells and effectively reverses glucocorticoid-induced apoptosis in these cells. OSA increases the resilience of vascular endothelial cells against oxidative stress and enhances osteoblast differentiation. Our study revealed that glucocorticoids activate endoplasmic reticulum stress, a process that mediates the apoptosis of vascular endothelial cells. OSA ameliorated the endoplasmic reticulum stress associated with glucocorticoids through the increased expression of p-Akt levels. In vivo, OSA treatment effectively improved SONFH by enhancing vascular endothelial cell function and promoting osteogenic differentiation. OSA counteracted the adverse effects of glucocorticoids both in vitro and in vivo, demonstrating a beneficial therapeutic effect on SONFH.
The aim of the study is to identify risk factors that lead to or predict premature treatment termination in psychosomatic hospitals. In the long-term, the study shall help to develop more precise prediction models that can enhance communication between therapists and patients about potential dropout and- if necessary- adaption of treatment in using a feedback loop.

Since it is still not clear which variables play a major role in predicting treatment termination in psychosomatic hospitals, the study design is exploratory and includes a broad range of intake patient characteristics. The purpose of this study is hereby, to develop a prediction model based on the information that are routinely assessed at intake. Therefore, three kind of variables are planned to be included: (1) demographic and other clinical variables (e.g. age, gender, ICD-10 diagnoses), (2) psychological questionnaire data (e.g. PHQ, SF-12, EB-45, IIP-32, OPD-SFK), and (3) physiological data (e.g. routine laboratory data, blood pressure). For the study, all patients that started inpatient psychotherapy at the medical centre Heidelberg between 2015 and January 2022 will be included, resulting in a sample size of approximately N = 2000. As the average dropout rate based on meta analytical results is around 20%, one can assume that up to 400 patients prematurely dropped out of treatment.

To calculate the prediction model, it is planned to use a machine learning approach which is highly functional in big data sets. Using a Random Forest Model for binary outcomes (regular treatment length vs. premature treatment termination) it is envisioned to identify variables that contribute to the prediction of premature treatment termination at intake. Additionally, waiting list effects will be considered by taking into account the waiting duration between the initial intake interview and the moment of the hospital admission. Therefore, the study will, for the first time, investigate a prediction model for premature treatment termination in inpatient psychotherapy including clinically relevant physiological data as well as waiting time effects in preparation of the psychosomatic treatment.
An integrated continuing medical education and treatment system is implemented as a system, a process, and an article of manufacture. A treatment goal memory stores clinical treatment goal data associated with at least one or more disease. An educational memory stores instructional education data associated with at least one disease and a treatment delta; the treatment delta is the difference between a clinical treatment goal data and corresponding data relevant to a disease of inquiry. A processor is adapted to receive a healthcare provider's selection of a disease of inquiry and electronic medical record data relevant to any disease of inquiry. The clinical treatment goal data may be queried for a disease matching a disease of inquiry. The goal data is compared with the electronic medical record data to determine a treatment delta. The continuing medical education data is selected based on the disease of inquiry and the treatment delta.
This group will undergo McHale Procedure.The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate.
Patients between 10-20 years of age with genetically determined cystic fibrosis followed at the university children's hospital Basel and university children's hospital Kinderklinik Bern, Switzerland. All patients will get the diagnostics for glucose tolerance with 3 different methods (CGMS, OGTT and optionally IVGTT).
Proparacaine Hydrochloride Ophthalmic Solution is a rapid acting local anesthetic suitable for ophthalmic use. With a single drop, the onset of anesthesia begins within 30 seconds and persists for 15 minutes or longer. 

The main site of anesthetic action is the nerve cell membrane where proparacaine interferes with the large transient increase in the membrane permeability to sodium ions that is normally produced by a slight depolarization of the membrane. As the anesthetic action progressively develops in a nerve, the threshold for electrical stimulation gradually increases and the safety factor for conduction decreases; when this action is sufficiently well developed, block of conduction is produced. 

The exact mechanism whereby proparacaine and other local anesthetics influence the permeability of the cell membrane is unknown; however, several studies indicate that local anesthetics may limit sodium ion permeability by closing the pores through which the ions migrate in the lipid layer of the nerve cell membrane. This limitation prevents the fundamental change necessary for the generation of the action potential.